Story perspectives

FDA panel eases peptide rules; Hims shares jump 13%

7/24/2026

Summary

FDA Loosens Peptides

The FDA Pharmacy Compounding Advisory Committee voted on July 23-24, 2026 to loosen restrictions on seven synthetic peptides.
Health Secretary Robert F. Kennedy Jr., a “big fan” of peptides, supported the change.
Panel members split, with Elizabeth Rebello voting no over safety and efficacy concerns.
FDA career scientists warned of insufficient human data, inconsistent manufacturing and possible immune-toxicity.
Seven of the 14 advisers have financial ties to peptide clinics or online businesses.

Summary

Hims Stock Surge

Hims & Hers Health stock surged up to 13% on July 23, outpacing the Nasdaq’s 1.96% decline.
BofA Securities raised its price target for Hims to $36 from $25.
The company's telehealth platform will sell compounded peptide treatments after the FDA finalizes the reclassification that would add BPC-157 to the 503A Bulk Drug Substances List.

History

Historical Context

In September 2012 a fungal meningitis outbreak linked to the New England Compounding Center’s contaminated steroid injections killed 64 patients and sickened more than 800, prompting the FDA, CDC and HHS to pass the 2013 Drug Quality and Security Act, which created 503 B outsourcing facilities. The FDA’s current Pharmacy Compounding Advisory Committee vote to reclassify synthetic peptides follows that regulatory overhaul.

1 of 3

FDA Loosens Peptides

The FDA Pharmacy Compounding Advisory Committee voted on July 23-24, 2026 to loosen restrictions on seven synthetic peptides.
Health Secretary Robert F. Kennedy Jr., a “big fan” of peptides, supported the change.
Panel members split, with Elizabeth Rebello voting no over safety and efficacy concerns.
FDA career scientists warned of insufficient human data, inconsistent manufacturing and possible immune-toxicity.
Seven of the 14 advisers have financial ties to peptide clinics or online businesses.

1 / 3